Fact CheckerSign in

NCT07342465Not yet recruiting

Gamma Light and Sound Stimulation in Schizophrenia

Safety, Feasibility, and Preliminary Efficacy of Non-invasive Gamma Neuromodulation in Individuals With Schizophrenia Spectrum Disorders

Source: ClinicalTrials.gov · Last updated 7 Oct 2026

Brief summary (registry, in English)

Schizophrenia (SZ) is a severe neuropsychiatric disorder impacting over 20 million people globally, causing significant personal and societal burdens, particularly due to cognitive deficits and negative symptoms inadequately treated by current therapies. To address this gap, investigators propose using Gamma Entrainment Using Sensory Stimulation (GENUS), a novel, home-based treatment involving synchronized 40 Hz light-and-sound stimulation aimed at improving neural synchrony, cognition, and SZ symptoms. This innovative approach leverages advanced neurostimulation, biological, and neuroimaging methods to directly target gamma dysfunction, fulfilling an urgent need for effective and accessible at-home therapies. The goal of this clinical trial is to learn about the safety and feasibility of gamma stimulation using light and sound. It will also learn if gamma stimulation using light and sound works to treat clinical symptoms and cognitive impairments in schizophrenia. The main questions it aims to answer are: 1. Is gamma stimulation safe for patients with schizophrenia spectrum disorders? 2. Does gamma stimulation alleviate clinical symptoms and cognitive impairments in schizophrenia patients? Participants will: 1. Have an acute 1-hour stimulation at MIT. 2. Come for a one-day visit to MIT for stimulation, neuroimaging, clinical, and cognitive evaluations.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
21 Nov 2025
Start date
Dec 2026
Primary completion date
Dec 2027
Lead sponsor
Massachusetts Institute of Technology
NCT number
NCT07342465

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From Dec 2026 to the primary completion date, Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • MRI contraindications such as the presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin or body.
  • Clinical conditions:
    • History of seizure or medical diagnosis of epilepsy.
    • ECT history \> 6 months
    • Female subjects who are pregnant or currently breastfeeding.
    • Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.
    • Significant neurological or medical disorders that may produce cognitive impairment.
    • Profound hearing or visual impairment.
    • Eye surgery in the last 3 months or are scheduled to have eye surgery in the next 3 months (during the study)

Other

  • Subjects who do not have healthcare
  • High myopia \< -7 diopters, or untreated cataracts that affect vision.

Who the study is looking for

  • Between 18-65 years of age.
  • A diagnosis of schizophrenia or schizoaffective disorder
  • No medication is an absolute exclusion. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: the patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS (central nervous system) active drugs.
  • The subject is willing to sign the informed consent document.
  • If the subject is deemed not to have the capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Massachusetts Institute of Technology (MIT)
Coordinator of this site? Confirm its status
CambridgeUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.